# Altimmune Inc. (ALT) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $3.42, market value $665 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Altimmune Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 16225.6×**. Each dollar of revenue is priced at 16225.6×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 1.4×**. The shares trade at 1.4× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -11.5%** (5-yr avg -16.5%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -39.2%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -34.7%**. Return on all capital, debt included, is -34.7%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -31.5%**. Each dollar of assets produces -31.5% of profit.

## Growth
- **Revenue growth (1 yr): 105.0%** (5-yr -65.3%/yr). Revenue grew 105.0% over the last year, against -65.3% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 25.4%**. Earnings per share rose 25.4%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.15**. Debt is 0.15 times equity: a conservative balance sheet.
- **Altman Z-score: 7.26**. A Z-score of 7.26 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Altimmune Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (9 analysts). 9 analysts cover Altimmune Inc.; the consensus is strong_buy, with an average price target of $17.22 (+404% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -3.9%** (YTD -5.3%, 3-mo 26.2%). The shares are down 3.9% over twelve months including dividends.
- **From 52-week high: -46.9%** (33.6% above the low). Trading 47% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 65**. An RSI of 65 is neutral.
- **Beta (1 yr): 1.47** (volatility 69%). Beta of 1.47 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ALT · Page: https://foliofundamentals.com/stocks/alt

Not investment advice.